Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 3Terminated 2Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 3

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 88Carboplatin 58pembrolizumab 57Biopsy 56Cisplatin 51Nivolumab 46Paclitaxel 39Radiotherapy 38Cyclophosphamide 38Gemcitabine 33Dexamethasone 31Radiation 30Bevacizumab 30atezolizumab 27Pemetrexed 27Etoposide 27olaparib 24Lenalidomide 24Doxorubicin 23X-Rays 22Vincristine 22Prednisone 22Leucovorin 22Immunoglobulin G 22Docetaxel 22Disulfides 22venetoclax 21durvalumab 21Rituximab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Axitinib × 30 days × Clear all
NCT03092856 2026-06-03

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

University of Southern California

Phase 2 Active not recruiting
62 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT03595124 2026-05-29

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
15 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell

NCT03172754 2026-05-22

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Fox Chase Cancer Center

Phase 1/2 Active not recruiting
98 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡